Keith Maher is listed as a director on 5 SEC Form D filings by 3 issuers between Jan 2020 and Jun 2022: TENAX THERAPEUTICS, INC. (Chapel Hill, NC — pharmaceuticals — 2022; $99.7M reported sold to 24 investors), TETRAPHASE PHARMACEUTICALS INC (Watertown, MA — pharmaceuticals — 2020; $44.8M reported sold to 14 investors) and KIORA PHARMACEUTICALS INC (Encinitas, CA — pharmaceuticals — 2020–2021; $15M reported sold to 32 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 2 years. Across those companies the filings report $159.4M sold in total.
Listed alongside Steven Boyd (5 shared filings), Bernard Malfroy-Camine (3 shared filings), Morton Goldberg (3 shared filings), Paul Chaney (3 shared filings), Praveen Tyle (3 shared filings) and 21 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Keith. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 5 public filings for Keith Maher and found 6 differences: Form D filed 17 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.